SEC Form 4	
------------	--

## FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

														OMB APPROVAL			
Sec oblig	eck this box if no tion 16. Form 4 o gations may con ruction 1(b).		STA		NT OF CHANGES IN BENEFICIAL OWNED d pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940							HIP	Estim		er: verage burd sponse:	3235-0287 en 0.5	
tran cont the secu to si cont	purchase or sale	le pursuant to a or written plan for of equity er that is intended tive defense															
1. Name and Address of Reporting Person <sup>*</sup> CUMMING JOHN W						2. Issuer Name <b>and</b> Ticker or Trading Symbol <u>T2 Biosystems, Inc.</u> [ TTOO ]							cable) or	10% Owner			
(Last) 101 H.	( ARTWELL .	First) AVENUE	(Middle)			3. Date of Earliest Transaction (Month/Day/Year) Officer (give below)									ve title Other (specify below)		
(Street) LEXIN (City)		∕IA State)	02421 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)								ndividual or Joint/Group Filing (Check Applicable e) Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Та		n-Deriv	ative Se	ecurities Acc	quired,	Dis	posed of	f, or Bene	eficially	y Owned	l				
1. Title of Security (Instr. 3) Date (Month/D						2A. Deemed Execution Date, if any (Month/Day/Year	3. Transa Code ( 8)			es Acquired Of (D) (Instr.		5. Amou Securitie Benefici Owned F Reporte	es ally Following	Form (D) o	vnership n: Direct r Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
							Code	ode V Amount		(A) or (D)	Price	Transact (Instr. 3	tion(s)			(1150.4)	
						curities Acqu ls, warrants,						Owned					
1. Title o	f 2.	3. Transaction	ction 3A. Deemed			5. Number	6. Date Exercisable and 7. Title and		7. Title and A	Amount	8. Price of	9. Numbe	er of	10.	11. Nature		

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Restricted Stock Units	(1)	11/04/2024		A		35,000		(2)	(2)	Common Stock	35,000	\$ <mark>0</mark>	35,000	D	

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.

2. On November 4, 2024, the reporting person was granted 35,000 RSU's that vest in two equal annual installments beginning on November 4, 2025. T This grant was contingent on stockholder approval of the amendment and restatement of Issuer's 2014 Incentive Award Plan. The Issuer's stockholders approved the amendment and restatement of the plan on December 30, 2024.

/s/ John Sprague, Attorney-in-01/02/2025

fact \*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

 $^{\ast}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.